London, 24 February 2009: EMEA, the European Medicines Agency, the body responsible for the evaluation and supervision of medicines for human use in Europe, today played host to EFPIA, the voice of the research-based pharmaceutical industry in Europe, for their 14th joint annual Information Day. The event gathered over 100 people from industry to meet with regulators in an exchange of views and review of performance.
Thomas Lönngren, Executive Director of EMEA opened the meeting emphasizing the value of such a dialogue in a time of increasing globalization and a rapidly changing regulatory environment. It was important to provide robust scientific assessment of the highest quality, but to do so in a cost-effective manner. For EFPIA, Director General Brian Ager commented “The need for symbiosis between industry and regulators is ever more acute; pipeline productivity is of concern to all, and pressure on payers is increasing; it is clear we need to work together to ensure we expedite efficiency.”
The format of the EMEA–EFPIA Information Day allows for formal feedback on a series of mutually agreed performance indicators, allowing for active debate on areas for improvement. It also permits an industry insight into the Agency’s work plan and workload in the medium term. The value of this ongoing discussion and the form it takes are of paramount importance to both bodies.
Amongst a number of issues addressed, the industry has concerns that a non-pragmatic approach to the paediatric legislation could lead to delays in adult medicines, something that was never envisaged. There was a consensus that the increasing number of committees involved in the authorization phases, including the pre- and post-phases, meant that coordination of dialogue with the various committees were a growing challenge.
Meanwhile the Agency pressed industry on the need to adopt standardized electronic submissions, and emphasizing that non-standard and paper-based submissions could not be prioritized. The Agency aims to migrate all new centralized product applications in the new format of e-CTD by 2012.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.